Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete

Karyopharm Therapeutics Inc.

U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.
Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.
Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.
Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.
Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.